Biotech | October 29, 2021
NH TherAguix releases new batch for AGuIX
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Subscribe To Our Newsletter & Stay Updated
